October 23–27, 2026 · Madrid · 176 items
Madrid floor. One post is one item; several people on the same trial or drug become a heat probe. The floor is paged by day; prelude discussion sits on the prelude board. Abstracts are linked, not reprinted, and other people's slides are not posted.
@A_May_MD @deathtouch2k Same HR, different trials. S1801: phase 2, n=313, clinically detectable III–IV, EFS. INTerpath-001: phase 3, n=1137, resected IIB–IV incl. node-negative IIB/C where neoadjuvant isn't on the table,
11 people · 11 posts · 2 topics
✈️ En route to Madrid for #ESMO26, landing just in time for the data to start Friday morning. Most excited for: VOLGA LBA2 in bladder cancer, INTerpath-001's first phase 3 neoantigen win, LITESPARK-011 final in kidney ca
ESMO 2026 | TOP 10 LUNG CANCER TRIALS TO WATCH! From DLL3 bispecifics and next-generation KRAS inhibitors to novel ADCs, major lung cancer data are coming at #ESMO26. 🔥 My Top 10 Trials 1.DeLLphi-305 | Tarlatamab + durv
Right now there's growing anticipation among HCPs for @NovartisCancer NATALEE trial 6-year breast cancer survival results due to be presented at #ESMO26, according to @CREATION Intelligence. We're tracking the HCP reacti
Tomorrow! Don’t miss Dr. Sara Tolaney (@stolaney1) at #ESMO26 as she discusses #ADC strategies in HER2-positive #BreastCancer across the first-line metastatic and early disease settings. 🗓️Friday, October 23 ⏰ 09:45 - 1
🚨 ESMO 2026 | TOP 10 GU CANCER TRIALS TO WATCH! From perioperative immunotherapy and AR pathway intensification to HIF-2α inhibition and long-term survival updates, GU oncology is set for some major presentations at #ES
KEYNOTE-975: adding pembro to definitive CRT didn't improve EFS in CPS>=10 esophageal/GEJ cancer. HR 0.97 (95% CI 0.77-1.23). Hierarchy stopped there; OS wasn't formally tested. Another reason not to assume IO helps ever
UNION: 3y EFS 91% vs 77% with SCRT/CAPOX/camrelizumab vs long-course CRT/CAPOX in rectal cancer. HR 0.33 (95% CI 0.15-0.71). Impressive signal. But RT schedule and IO both changed, so this doesn't isolate the benefit of
ARION adds to the negative IO+CRT story in esophageal cancer. Durvalumab + FOLFOX/50 Gy in 25 fx: PFS HR 0.91 (95% CI 0.55-1.49), OS HR 0.99. Only 112 pts, mostly SCC. No demonstrated benefit from adding durva here. #ESM
Encouraging pancreas SBRT data from MASTERPLAN. Adding 40 Gy/5 fx cut 12mo locoregional recurrence from 52% to 20% (P=.022). OS 22 vs 14mo, but this is a 74-pt phase II with mixed resectability. Promising; not definitive
The benifit is same as if you give neo adjuvant pembrolizumab? - cross trial comparisons- Will this hold true if Pembrolizumab is given neoadjuvant in control arm ? We don't know. @OncBrothers @OncoAlert @myESMO #esmo26
🚨 ESMO 2026 | PANKU-Breast01 (LBA50) #esmo26 Impressive phase III results for izalontamab brengitecan (iza-bren), a bispecific EGFR/HER3 ADC, in previously treated MBC HR +ve Her2 -ve Iza-bren vs physician's choice chem